Obesity is one the most prevalent long-term health conditions in the UK. 15 million people suffer with it and 1 in 3 children now have it. The downstream complications cost the nation £58 billion each year and the NHS spends £6.1 billion treating its sequelae but only spends £100 million on treating the condition itself.
In one of it’s regular all-staff ‘lunch and learn’ problem solving sessions, CF asked itself how obesity policy, commissioning and pathway design should evolve to meet this great challenge in the context of huge strides in the understanding of its aetiology (70-90% genetic and heavily psychosocial) and treatment (with efficacious new therapeutic agents coming to market).
